-
Biogen Inc. (BIIB)
-
Abbott Laboratories (ABT)
-
Eli Lilly and Company (LLY)
-
Pfizer Inc. (PFE)
-
Novo Nordisk A/S (NVO)
Q: November 2020 was your last response on the business fundamentals of this company. Recognizing that the stock price has dropped even more since then, what has changed with this company's outlook when comparing time periods?
How is its balance sheet and drug pipeline compared to Pfizer?
Pfizer is clearly more of an income play but that aside, do you favour one or the other for any particular reason?
How is its balance sheet and drug pipeline compared to Pfizer?
Pfizer is clearly more of an income play but that aside, do you favour one or the other for any particular reason?